drugset / Trial / NCT03897543
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
Open-label, uncontrolled, phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma
Timeline
- Start
- 2019-08-30
- Primary completion
- 2021-06-30
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABX196 | Small molecule | 0.1 ug | Intramuscular |
| Subject | ABX196 | Small molecule | 0.2 ug | Intramuscular |
| Subject | ABX196 | Small molecule | 0.4 ug | Intramuscular |